Episode
🎧 START pod: Arvid Gollwitzer, Co-Founder, Anto Bio: “A Foundation Model for Microbial Communities”
- Podcast
- START
- Published
- May 12, 2026
- Duration seconds
- 853
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/3d82419a
Actions
POST https://stenobird.com/v1/public/podcasts/start-7171926/episodes/start-pod-arvid-gollwitzer-co-founder-anto-bio-a-foundation-model-for-microbial-communities/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/start-7171926/start-pod-arvid-gollwitzer-co-founder-anto-bio-a-foundation-model-for-microbial-communities.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
A drug was approved in China Then it failed clinical trials in the US No one could figure out why The answer was hiding in the gut microbiome Anto Bio’s model helped identify it 99% of the genes in your body aren't yours They belong to your microbiome Over two-thirds of drugs are heavily affected by how your gut processes them But the microbiome data was too noisy. Too messy. Petabytes of it just sitting there Anto Bio's mission: make the gut microbiome computable for the first time They're building foundation models that help pharma design drugs that work for more people 🎙️ Arvid Gollwitzer, Co-Founder, Anto Bio on Fondo START pod 1:18 What Anto Bio is building and why it's novel 2:10 Why this didn't exist before 3:05 99% of your genes aren't yours 4:00 Why pharma ignoring the microbiome is a huge problem 5:04 The microbiome is modifiable 6:30 Modeling microbiome differences across populations 7:00 Drug approved in China, failed in the US, and how Anto found out why 8:02 How many drugs are affected by microbiome metabolism 10:00 GLP-1s and the gut microbiome connection 12:42 The biggest unsolved variable in drug development Learn more at www.anto.bio